As hCA IX and XII are validated anti-tumour targets5, with one sulphonamide (SLC-0111) in Phase Ib/II clinical trials, finding derivatives with a better selectivity for inhibiting the tumour-associated isoforms over the cytosolic ones, as the homosulfocoumarins reported here, is of crucial importance. This evidence concerns the gene CCL21 and neoplasm.